Protagenic Therapeutics (NYSE: PTIX) — Perfil da empresa, notícias e dados financeiros
Protagenic Therapeutics focuses on innovative treatments for CNS disorders, utilizing natural brain peptides to improve mental health.
Protagenic Therapeutics
Protagenic Therapeutics (NASDAQ:PTIX) is a biotechnology firm focused on developing innovative treatments aimed at modulating the body's stress response system to address central nervous system disorders, including anxiety, depression, and substance dependence. Their work revolves around leveraging the therapeutic potential of natural brain peptides to create novel, first-in-class medications. A key project in their pipeline is the development of PT00114, a proprietary peptide designed to target and regulate the stress response pathway at its core, offering a new approach to treating a range of psychiatric and neurological conditions. Through its research and development efforts, Protagenic Therapeutics aims to revolutionize the understanding and treatment of mental health disorders, striving to improve patient outcomes and quality of life.
Resumo
Operações
Produtos e/ou serviços de Protagenic Therapeutics
- Developing PT00114, a proprietary peptide therapeutic for treatment-resistant depression, addressing a significant unmet need in mental health.
- Exploring PT00114's potential applications beyond depression to other stress-related neuropsychiatric disorders, expanding its therapeutic scope.
- Initiating preclinical studies to assess the safety and efficacy of new compounds targeting stress-related disorders, aiming for breakthroughs in neuropsychiatry.
- Advancing a portfolio of neuroactive peptides derived from brain activity regulation research, focusing on novel mental health therapies.
- Leveraging a proprietary technology platform for discovering and developing peptides influencing the central nervous system, aiming to introduce innovative treatments.
- Collaborating with academic and research institutions to enhance their discovery pipeline and accelerate the development of promising therapeutic candidates.
equipe executiva do Protagenic Therapeutics
- Dr. Garo H. Armen Ph.D.Executive Chairman
- Dr. Alexander Kenneth Arrow C.F.A., M.D.Chief Financial Officer
- Dr. Robert Benjamin Stein M.D., Ph.D.Chief Medical Officer
Principais indicadores financeiros
Resultados divulgados pela Protagenic Therapeutics.
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| — | -5,8 mi | -5,2 mi | |
| 0 | -5,7 mi | -5,5 mi | |
| 0 | -4,5 mi | -5 mi | |
| 0 | -3,6 mi | -3,6 mi |